Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Cancer Type/Condition:  Nonmelanomatous skin (squamous and basal cell)
Trial Type:  All
Trial Status:  Active
Results 1-25 of 89 for your search:
Start Over
Imiquimod 5% Cream for the Treatment of Periocular Basal Cell Carcinoma
Phase: Phase IV
Type: Treatment
Status: Active
Age: 18 to 90
Sponsor: Other
Protocol IDs: 0559/07, NCT00803907
Imiquimod 3.75% Cream in Combination With Cryotherapy in the Treatment of Hypertrophic Actinic Keratoses
Phase: Phase IV
Type: Prevention, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 10-0933, NCT01229319
Forehead Scars Following Mohs Micrographic Surgery and Reconstruction for Skin Cancer
Phase: Phase IV
Type: Supportive care
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: Mann-Cohen Version 2, NCT01459666
Imiquimod Versus Photodynamic Therapy of Actinic Keratoses in Organ Transplant Recipients
Phase: Phase IV
Type: Treatment
Status: Active
Age: 18 to 80
Sponsor: Other
Protocol IDs: IPDTAKOTR/V06/28.12.11, NCT01538901
Risk of Squamous Cell Carcinoma on Skin Areas Treated With Ingenol Mebutate Gel, 0.015% and Imiquimod Cream, 5%
Phase: Phase IV
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: LP0041-63, 2012-003112-31, NCT01926496
Safety and Efficacy of Ingenol Mebutate 0.05% Gel When Used After Cryotherapy in the Hypertrophic Actinic Keratoses
Phase: Phase IV
Type: Prevention, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: GCO 13-0142, NCT02251652
IM Versus 5-FU Versus IMI Versus MAL-PDT in Treatment of Actinic Keratosis
Phase: Phase IV
Type: Health services research, Prevention, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: NL50621.068.14, 836031011, 2014-003691-23, NCT02281682
Fractional CO2 Laser Assisted Photodynamic Therapy
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: H-1-2010-044, 2010-020179-22, NCT01260987
Topical Green Tea Ointment in Treatment of Superficial Skin Cancer
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: NL47392.068.13, NCT02029352
Periocular Basal Cell Carcinoma (BCC): Permanent vs. Frozen Section Pathological Control
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 01, NCT00663650
5fluorouracil for Advanced Photoaging
Phase: Phase III
Type: Treatment
Status: Active
Age: 50 to 75
Sponsor: Other
Protocol IDs: Carol2011, NCT01405144
Safety and Efficacy Study of Photodynamic Therapy With Levulan Kerastick + Blue Light for Actinic Keratoses on the Upper Extremities
Phase: Phase III
Type: Prevention, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CP0108, NCT02137785
Safety and Efficacy Study for the Treatment of Non-Aggressive Basal Cell Carcinoma With Photodynamic Therapy
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: ALA-BCC-CT008, 2013-003241-42, NCT02144077
Surgery Versus Combined Treatment With Curettage and Imiquimod for Nodular Basal Cell Carcinoma
Phase: Phase III
Type: Health services research, Supportive care, Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: Other
Protocol IDs: NL50433.068.14, NCT02242929
Investigate the Diagnostic Value and Possibilities of OCT in Non-Melanoma Skin Cancer.
Phase: Phase II, Phase I
Type: Diagnostic
Status: Active
Age: Over 18
Sponsor: Other
Protocol IDs: oct-MM-2005, Grant # BIOPHOT 26-02-0020, NCT00390351
Safety, Tolerability and Performance of SmartMatrix Dermal Replacement Scaffold
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: SML001/13, NCT02059252
Transient Infrared Imaging for Early Detection of Skin Cancer
Phase: Phase II, Phase I
Type: Screening
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 10-304, NCT02154451
Superficial Basal Cell Cancer's Photodynamic Therapy: Comparing Three Photosensitises: HAL and BF-200 ALA Versus MAL
Phase: Phase II, Phase I
Type: Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: Other
Protocol IDs: JointAPHSHC, 2014-002746-50, NCT02367547
A Study in Advanced Solid Tumors
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 13420, I4E-MC-JXBB, NCT01063075
Panitumumab (Vectibix®) in Cutaneous Squamous Cell Carcinoma (SCC)
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: Luc 09-002, NCT01129154
Treatment of Basal Cell Carcinomas With Methyl Aminolevulinate and Daylight
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 2010-024517-31, NCT01349361
Weekly Docetaxel, Cisplatin, and Cetuximab (TPC) in Palliative Treatment of Patients With Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Phase: Phase II
Type: Treatment
Status: Active
Age: 16 and over
Sponsor: Other
Protocol IDs: ENT0033, SU-08222011-8290, 22329, NCI-2011-03271, NCT01437449
Study Evaluating the Efficacy of Oral Vismodegib in Various Histologic Subtypes
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 to 90
Sponsor: Other
Protocol IDs: ML28485, NCT01700049
Phase II Study of Radiation Therapy and Vismodegib for Advanced Head/Neck Basal Cell Carcinoma
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CC#122011, NCT01835626
Safety and Efficacy of Oshadi D and Oshadi R in Basal Cell Carcinoma Patients Prior to Tumor Excision a Phase 2 Study
Phase: Phase II
Type: Treatment
Status: Active
Age: Over 21
Sponsor: Other
Protocol IDs: OS-BCC-P2-01, NCT02007317
Start Over